This study is accepting new patients by invitation only
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
Crohn's Disease Upadacitinib ABT-494 Extension Study Efficacy Safety Maintenance Study Crohn Disease
Lead Scientist at UCSF
- Melvin Heyman
Professor, Pediatrics. Authored (or co-authored) 306 research publications.
- accepting new patients by invitation only
- Start Date
- Completion Date
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- Phase 3
- Study Type
- Last Updated